QUANTUM BIOPHARMA-B SUB VOT (QNTM) Forecast, Price Target & Analyst Ratings
NASDAQ:QNTM • CA74764Y2050
3.5 USD
-0.09 (-2.51%)
Last: Mar 6, 2026, 08:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for QUANTUM BIOPHARMA-B SUB VOT (QNTM).
Forecast Snapshot
Consensus Price Target
$31.01
+ 785.97% Upside
Next Earnings Forecast
Release DateMar 26, 2026
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$31.01
Upside
+ 785.97%
From current price of $3.50 to mean target of $31.01, Based on 7 analyst forecasts
Low
$30.70
Median
$31.01
High
$31.92
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
7 analysts have analysed QNTM and the average price target is 31.01 USD. This implies a price increase of 785.97% is expected in the next year compared to the current price of 3.5.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
QNTM was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about QNTM.
In the previous month the buy percentage consensus was at a similar level.
QNTM was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 26, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 66.5K | 186.7K 180.75% | -100.00% | N/A | N/A | N/A | N/A | ||
| EBITDA YoY % growth | N/A | -24.412M | -23.541M 3.57% | N/A -10.20% | N/A -14.48% | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.659M -1,907.02% | -24.549M -823.13% | -25.898M -5.50% | N/A -15.23% | N/A -13.07% | N/A | N/A | N/A | |
| Operating Margin | N/A | -36,915.64% | -13,871.56% | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -352.72 14.05% | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
QUANTUM BIOPHARMA-B SUB VOT / QNTM Forecast FAQ
What do analysts expect the price target to be for QUANTUM BIOPHARMA-B SUB VOT (QNTM)?
7 analysts have analysed QNTM and the average price target is 31.01 USD. This implies a price increase of 785.97% is expected in the next year compared to the current price of 3.5.
Can you provide the upcoming earnings date for QUANTUM BIOPHARMA-B SUB VOT?
QUANTUM BIOPHARMA-B SUB VOT (QNTM) will report earnings on 2026-03-26.